Topoisomerase inhibitors as therapeutic weapons

Bibliography

• GILES GI, SHARMA RP: Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem. (2005) 1(4):383-394.
   PubMedGoogle Scholar
• BALAÑA-FOUCE R, REDONDO CM, PÉREZ-PERTEJO Y, DÍAZ-GONZÁLEZ R, REGUERA RM: Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov. Today (2006) 11(15,16):733-740.
   Google Scholar
• REGUERA RM, REDONDO CM, GUTIÉRREZ DE PRADO R, PÉREZ-PERTEJO Y, BALAÑA-FOUCE R: DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim. Biophys. Acta. (2006) 1759:117-131.
   PubMedGoogle Scholar
• PASTOR N, CORTÉS F: Bufalin influences the repair of X-ray-induced DNA breaks in Chinese hamster cells. DNA Repair (2003) 2:1353-1360.
   PubMedGoogle Scholar
• HAYASHI S, HATASHITA M, MATSUMOTO H, SHIOURA H, KITAI R, KANO E: Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. Int. J. Mol. Med. (2006) 18(5):909-915.
   PubMedGoogle Scholar
• CORTÉS F, PASTOR N: Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis (2003)18:105-112.
   PubMedGoogle Scholar
• CORTÉS F, PASTOR N, MATEOS S, DOMÍNGUEZ I: Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat. Res. (2003) 543:59-66.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DM, LATHAM MD, ROSS WE: Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse and Chinese hamster ovary cells. Cancer Res. (1987) 47:3973-3979.
   PubMed Web of Science ®Google Scholar
• LIU LF: DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. (1989) 58:351-375.
   PubMed Web of Science ®Google Scholar
• BURDEN DA, OSHEROFF N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta. (1998) 1400:139-154.
   PubMed Web of Science ®Google Scholar
• WANG JC: DNA topoisomerases. Annu. Rev. Biochem. (1996) 65:635-692.
   PubMed Web of Science ®Google Scholar
• SANDER M, HSIEH T, UDVARDY A, SCHEDL P: Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding. J. Mol. Biol. (1987) 194:219-229.
   PubMed Web of Science ®Google Scholar
• SPITZNER JR, MULLER MT: A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. (1988) 16:5533-5556.
   PubMed Web of Science ®Google Scholar
• LEE MP, SANDER M, HSIEH T: Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites. J. Biol. Chem. (1989) 264:21779-21787.
   PubMed Web of Science ®Google Scholar
• POMMIER Y, CAPRANICO G, ORR A, KOHN KW: Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. J. Mol. Biol. (1991) 222:909-924.
   PubMedGoogle Scholar
• ADAMS DJ: The impact of tumor physiology on camptothecin-based drug development. Curr. Med. Chem. Anticancer Agents (2005) 5:1-13.
   PubMedGoogle Scholar
• SRIRAM D, YOGEESWARI P, THIRUMURUGAN R, BAL TR: Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat. Prod. Res. (2005) 19(4):393-412.
   PubMed Web of Science ®Google Scholar
• THOMAS CJ, RAHIER NJ, HECHT SM: Camptothecin: current perspectives. Bioorg. Med. Chem. (2004) 12:1585-1604.
   PubMed Web of Science ®Google Scholar
• POMMIER Y: Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer (2006) 6(10):789-802.
   PubMed Web of Science ®Google Scholar
• WAKELEE HA, SIKIC BI: Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clin. Lung Cancer (2005) 7(Suppl. 1):S6-S12.
   Web of Science ®Google Scholar
• SAIF MW, DIASIO RB: Edotecarin: a novel topoisomerase I inhibitor. Clin. Colorectal Cancer (2005) 5(1):27-36.
   PubMedGoogle Scholar
• CHEN AY, LIU LF: DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. (1994) 34:191-218.
   PubMed Web of Science ®Google Scholar
• FROELICH-AMMON SJ, OSHEROFF N: Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. (1995) 270:21429-21432.
   PubMed Web of Science ®Google Scholar
• BINASCHI M, ZUNINO F, CAPRANICO G: Mechanism of action of DNA topoisomerase inhibitors. Stem Cells (1995) 13:369-379.
   PubMed Web of Science ®Google Scholar
• NITISS JL, BECK WT: Antitopoisomerase drug action and resistance. Eur. J. Cancer (1996) 32A:958-966.
   PubMed Web of Science ®Google Scholar
• ANDOH T, ISHIDA R: Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta. (1998) 1400:155-171.
   PubMed Web of Science ®Google Scholar
• LARSEN AK, ESCARGUEIL AE, SKLADANOWSKI A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. (2003) 99:167-181.
   PubMed Web of Science ®Google Scholar
• CHEN M, BECK WT: Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. (1993) 53(24):5946-5953.
   PubMed Web of Science ®Google Scholar
• BOJANOWSKI K, LELIEVRE S, MARKOVITS J, COUPREE J, JACQUEMIN-SABLON A, LARSEN AK: Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA. (1992) 89:3025-3029.
   PubMed Web of Science ®Google Scholar
• JENSEN PB, SØRENSON BS, DEMANT EJ et al.: Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)-methanesulfon- m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res. (1990) 50:3311-3316.
   PubMed Web of Science ®Google Scholar
• DRAKE FH, HOFMANN GA, MONG SM et al.: In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. (1989) 49:2578-2583.
   PubMed Web of Science ®Google Scholar
• BORITZKI TJ, WOLFARD TS, BESSERER JA, JACKSON RC, FRY DW: Inhibition to type II topoisomerase by fostriecin. Biochem. Pharmacol. (1998) 37:4063-4068.
   Google Scholar
• UTSUMI H, SHIBUYA ML, KOSAKA T, BUDDENBAUM WE, ELKIND MM: Abrogation by novobiocin of cytotoxicity due to the topoisomerase II inhibitor amsacrine in Chinese hamster cells. Cancer Res. (1990) 50:2577-2581.
   PubMedGoogle Scholar
• JENSEN LH, NITISS KC, ROSE A et al.: A novel mechanism of cell killing by antitopoisomerase II bis-dioxopiperazines. J. Biol. Chem. (2000) 275:2137-2146.
   PubMed Web of Science ®Google Scholar
• HUANG KC, GAO H, YAMASAKI EF et al.: Topoisomerase II poisoning by ICRF-193. J. Biol. Chem. (2001) 276:44488-44494.
   PubMed Web of Science ®Google Scholar
• HAJJI N, PASTOR N, MATEOS S, DOMÍNGUEZ I, CORTÉS F: DNA strand breaks induced by the antitopoisomerase II bis-dioxopiperazine ICRF-193. Mutat. Res. (2003) 530:35-46.
   PubMed Web of Science ®Google Scholar
• CORTÉS F, PIÑERO J: Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured CHO cells. Cancer Chemother. Pharmacol. (1994) 34:411-415.
   PubMed Web of Science ®Google Scholar
• DENNY WA, BAGULEY BC: Dual topoisomerase I/II inhibitors in cancer therapy. Curr. Top. Med. Chem. (2003) 3(3):339-353.
   PubMed Web of Science ®Google Scholar
• DITTRICH C, COUDERT B, PAZ-ARES L et al.: Phase II study of XR 5000(DACA), an inhibitor of topoisomerase I and II, administered as a 120 h infusion in patients with non-small cell lung cancer. Eur. J. Cancer (2003) 39(3):330-334.
   PubMed Web of Science ®Google Scholar
• WASSERMANN K, MARKOVITS J, JAXEL C, CAPRANICO G, KOHN KW, POMMIER Y: Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol. (1990) 38:38-45.
   PubMed Web of Science ®Google Scholar
• ETIÉVANT C, KRUCZYNSKI A, BARRET JM et al.: F11782, a dual inhibitor of topoisomerase I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother. Pharmacol. (2000) 46:102-113.
   Google Scholar
• HAJJI N, MATEOS S, PASTOR N, DOMÍNGUEZ I, CORTÉS F: Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat. Res. (2005) 583:26-35.
   PubMed Web of Science ®Google Scholar
• WANG B, PERCHELLET EM, WANG Y, TAMURA M, HUA DH, PERCHELLET JP: Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities. Anticancer Drugs (2003) 14(7):503-514.
   PubMedGoogle Scholar
• SISSI C, PALUMBO M: The quinolone family: from antibacterial to anticancer agents. Curr. Med. Chem. Anticancer Agents (2003) 3(6):439-450.
   PubMedGoogle Scholar
• HEATON VJ, AMBLER JE, FISHER LM: Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. (2000) 44(11):3112-3117.
   PubMed Web of Science ®Google Scholar
• JACOBS MR: Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr. Pharm. Des. (2004) 10(26):3213-3220.
   PubMedGoogle Scholar
• WILES JA, HASHIMOTO A, THANASSI JA et al.: Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J. Med. Chem. (2006) 49(1):39-42.
   PubMed Web of Science ®Google Scholar
• MANI N, GROSS CH, PARSONS JD et al.: In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob. Agents Chemother. (2006) 50(4):1228-1237.
   PubMed Web of Science ®Google Scholar
• CHENG B, SHUKLA S, VASUNILASHORN S, MUKHOPADHYAY S, TSE-DINH YC: Bacterial cell killing mediated by topoisomerase I DNA cleavage activity. J. Biol. Chem. (2005) 280(46):38489-38495.
   PubMedGoogle Scholar
• VILLA H, OTERO MARCOS AR, REGUERA RM et al.: A novel active DNA topoisomerase I in Leishmania donovani. J. Biol. Chem. (2003) 278:3521-3526.
   PubMedGoogle Scholar
• PROULX ME, DESORMEAUX A, MARQUIS JF, OLIVIER M, BERGERON MG: Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob. Agents Chemother. (2001) 45(9):2623-2627.
   PubMed Web of Science ®Google Scholar
• MITTRA B, SAHA A, CHOWDHURY AR et al.: Luteolin, an abundant dietary component is a potent antileishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol. Med. (2000) 6(6):527-541.
   PubMed Web of Science ®Google Scholar
• SUNDRIYAL S, SHARMA RK, JAIN R: Current advances in antifungal targets and drug development. Curr. Med. Chem. (2006) 13(11):1321-1335.
   PubMed Web of Science ®Google Scholar
• SHEN LL, BARANOWSKI J, FOSTEL J, MONTGOMERY DA, LARTEY PA: DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob. Agents Chemother. (1992) 36(12):2778-2784.
   PubMed Web of Science ®Google Scholar
• FOSTEL J, MONTGOMERY D: Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans. Antimicrob. Agents Chemother. (1995) 39(3):586-592.
   PubMedGoogle Scholar
• GOLDMAN GH, YU C, WU HY, SANDERS MM, LA VOIE EJ, LIU LF: Differential poisoning of human and Aspergillus nidulans DNA topoisomerase I by bi- and terbenzimidazoles. Biochemistry (1997) 36(21):6488-6494.
   PubMedGoogle Scholar
• KHAN SI, NIMROD AC, MEHRPOOYA M, NITISS JL, WALKER LA, CLARK AM: Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob. Agents Chemother. (2002) 46(6):1785-1792.
   PubMedGoogle Scholar
• MANOCHAKIA RN, MILLER KC, CHANAN-KHAN AA: Bortezomib in combination with pegylated liposomal Doxorubicin for the treatment of multiple myeloma. Clin. Lymphoma Myeloma. (2007) 7(4):266-271.
   PubMedGoogle Scholar
• AMINOVA LR, CHAVEZ JC, LEE J et al.: Prosurvival and prodeath effects of hypoxia-inducible factor-1α stabilization in a murine hippocampal cell line. J. Biol. Chem. (2005) 280(5):3996-4003.
   PubMed Web of Science ®Google Scholar
• RAPISARDA A, URANCHIMEG B, SORDET O, POMMIER Y, SHOEMAKER R H, MELILLO G: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1. Mechanism and therapeutic implications. Cancer Res. (2004) 64:1475-1482.
   PubMed Web of Science ®Google Scholar